Oncology Biosimilars Market Shows Expected Growth from 2017-2022

Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the oncology biosimilars market over the forecast period

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

Get The Holiasitc SAMPLE With TOC:

https://www.coherentmarketinsights.com/insight/request-sample/1305

North America is expected to dominate the oncology biosimilars market over the forecast period

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.

Europe market is also expected to witness rapid growth over the forecast period. This is due to expected launch of major products in the market over the forecast period. Europe-based leading generic manufacturers such as Sandoz (a Novartis International AG’s division) and Mylan N.V. has shown interest in this field. Mylan N.V. has entered into a collaboration agreement with Biocon Limited to develop biosimilars in 2009. The duo got approval for their first biosimilar product in 2017 in U.S. and also, European Medicines Agency (EMA) has accepted resubmission for their Herceptin biosimilar in the same year. With increasing number of approved products, the oncology biosimilars market is expected to witness significant growth in the region over the forecast period.

Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/1305

You may be interested

Researchers Developed Plasma-treated Fuel Cell
Business
Business

Researchers Developed Plasma-treated Fuel Cell

Mohit Joshi - October 22, 2018

Researchers developed plasma-treated fuel cell, according to a study published on September 7, 2018. This study was conducted by the researchers at the University of British Columbia.…

Shigella Vaccines Market Progresses for Huge Profits by 2026
Business
Business

Shigella Vaccines Market Progresses for Huge Profits by 2026

Mohit Joshi - October 22, 2018

The Shigella Vaccines Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Shigella Vaccines Market research report. The report has…

Brain Health Devices Market Set to Take Off by 2026 To Gather Huge Revenues
Business
Business

Brain Health Devices Market Set to Take Off by 2026 To Gather Huge Revenues

Mohit Joshi - October 22, 2018

The Brain Health Devices Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Brain Health Devices Market research report. The…

Most from this category